Schizophrenia Drugs Market Size, Share, Growth Analysis, By Drug Class(Second-generation antipsychotics, third-generation antipsychotics, and others), By Treatment(Oral antipsychotics, and injectable antipsychotics), By Distribution channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and others), By Region - Industry Forecast 2024-2031

Global Schizophrenia Drugs Market size was valued at USD 7.50 billion in 2022 and is poised to grow from USD 7.90 billion in 2023 to USD 11.94 billion by 2031, growing at a CAGR of 5.3% in the forecast period (2024-2031).

The rising issue of substance abuse around the world and increasing awareness regarding mental health are projected to alter the global schizophrenia drugs market outlook in the future. Surge in cases of schizophrenia, growing investments in the development of novel pharmaceuticals for mental health issues, and growing awareness regarding symptoms of schizophrenia are other factors that are slated to boost sales of schizophrenia drugs on a global level. Increasing investments in the research and development of novel schizophrenia treatment therapies and drugs around the world are also slated to create new opportunities for schizophrenia drug companies going forward. On the contrary, high costs of schizophrenia treatment, limited efficacy of drugs, complexity in drug development and approval, and growing incidence of treatment resistant schizophrenia are expected to be key restraints for schizophrenia drug providers around the world through 2031 and beyond. 

US Schizophrenia Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.